Incorporating the voice of patient in pediatric assent forms

Future-Proofing SaMD: Regulatory Strategies for Medical Software Development

The rise of software as a medical device (SaMD) is transforming healthcare by enabling real-time data analysis, personalized care and predictive diagnostics.

Implementing a critical infectious disease protocol

Detecting the Undetectable: The Rising Potential of Liquid Biopsies in Oncology

In the past decade, a vial of blood has become a powerful window into cancer biology. Liquid biopsies, once limited to detecting specific mutations in advanced lung cancer, now offer a dynamic, real-time view of tumor genetics across multiple cancer types.

Key challenges in pediatric vaccine trials in low- and middle- income countries

Low- and middle-income countries (LMICs) bear a disproportionate burden of infectious diseases, with 90% of preventable cases occurring in these regions.

Highlighting Fortrea’s commitment to advancing rare disease clinical research

Over the last 5 years, our team at Fortrea has supported more than 820 rare disease studies, each with its own challenges and complexities.

See how we navigated complexities in a Phase I ICU trial

Recent years have seen a growing need for advanced critical care solutions, driven by factors such as an aging population, emerging infectious diseases and increasingly complex medical interventions.

Rapid diagnostic advantages in clinical research

The COVID-19 pandemic demonstrated how lateral flow point-of-care (POC) testing can improve target population enrichment and decrease loss of patients to key analysis sets once confirmatory testing becomes available.

Leveraging Technology for Vaccine Trial Surveillance

Vaccine trial sponsors face mounting pressure to accelerate development timelines while upholding the highest standards of data quality and participant safety.

Streamlining Site Selection and Participant Compliance for Vaccine Trials 

Two critical factors can make or break a large-scale vaccine trial: site selection and participant compliance.